Stock ELDN ELEDON PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

All News Eledon Pharmaceuticals, Inc.

Equities

ELDN

US28617K1016

Real-time Estimate Cboe BZX
Other stock markets
 02:50:23 2024-06-12 pm EDT 		5-day change 1st Jan Change
3.005 USD +3.62% Intraday chart for Eledon Pharmaceuticals, Inc. +6.69% +68.33%
Jun. 03 Eledon Pharmaceuticals, Inc. Presents Updated Data from Ongoing Phase 1B Trial Evaluating Tegoprubart for Prevention of Rejection in Kidney Transplantation CI
May. 13 Eledon Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Eledon Presents Updated Data from Ongoing Phase 1b Trial Evaluating Tegoprubart for Prevention of Rejection in Kidney Transplantation
GL
Eledon Pharmaceuticals, Inc. Presents Updated Data from Ongoing Phase 1B Trial Evaluating Tegoprubart for Prevention of Rejection in Kidney Transplantation
CI
Eledon Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Eledon Pharmaceuticals Reports First Quarter 2024 Operating and Financial Results
GL
Eledon Pharmaceuticals to Present Updated Data from Ongoing Phase 1b Trial of Tegoprubart in Patients Undergoing Kidney Transplantation at the American Transplant Congress
GL
Eledon Pharmaceuticals, Inc. announced that it has received $49.99901 million in funding
CI
Eledon Announces Clinical Progress with Tegoprubart in the Prevention of Transplant Rejection
GL
Eledon Pharmaceuticals, Inc. Announces Clinical Progress with Tegoprubart in the Prevention of Transplant Rejection
CI
Eledon Pharmaceuticals Announces Oversubscribed $50 Million Private Placement
GL
Eledon Pharmaceuticals, Inc. announced that it expects to receive $49.99901 million in funding
CI
Eledon Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Eledon Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Operating and Financial Results
GL
Eledon Pharmaceuticals Says 12th Participant Enrolled in Tegoprubart Trial; Shares Rise After Hours
MT
Eledon Pharmaceuticals Announces 12th Participant Enrolled in Phase 2 BESTOW Trial Evaluating Tegoprubart for the Prevention of Organ Rejection
GL
Eledon Pharmaceuticals Announces 12th Participant Enrolled in Phase 2 BESTOW Trial Evaluating Tegoprubart for the Prevention of Organ Rejection
CI
Sector Update: Health Care Stocks Higher in Late Afternoon Trading
MT
Sector Update: Health Care
MT
Eledon Pharmaceuticals Says Tegoprubart Used in Kidney Transplant From Pig to Human
MT
Eledon Pharmaceuticals Announces Use of Tegoprubart in First-ever Transplant of Genetically Modified Kidney from a Pig to a Human
GL
Eledon Pharmaceuticals Announces Use of Tegoprubart in First-ever Transplant of Genetically Modified Kidney from a Pig to a Human
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ELDN Stock
  4. News Eledon Pharmaceuticals, Inc.